Journals / Turkish Journal of Medical Sciences / 1999 / Cilt: 29 - Sayı: 6

Effect of etidronate on urinary calcium / creatinin ratio in postmenopausal women: A prospective, randomized, placebo controlled study

Pages
683–687
Publication Date
2022-11-04
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In conclusion, etidronate is effective in postmenopausal women and the effectiveness of treatment may be followed up by measuring uCa/Cr which is a simple and cheap parameter of determining the effectivensess of etidronate in prevention of osteoporosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:There are both histomorphometric and nonhistomorphometric studies confirming that etidronate reduces bone resorption.
📊
Key Findings & Data:Eighty-one postmenopausal women aged 40 to 65 included into the study to investigate the effects of etidronate on uCa/Cr in a prospective, randomised, placebo controlled clinical trial.
💡
Conclusion & Impact:In conclusion, etidronate is effective in postmenopausal women and the effectiveness of treatment may be followed up by measuring uCa/Cr which is a simple and cheap parameter of determining the effectivensess of etidronate in prevention of osteoporosis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

There are both histomorphometric and nonhistomorphometric studies confirming that etidronate reduces bone resorption. In this study, we have examined urinary Calcium/Creatinine ratio (uCA/Cr) as a biochemical marker of bone turnover to show the effectiveness of etidronate and whether it could be used as a follow-up parameter of treatment. Eighty-one postmenopausal women aged 40 to 65 included into the study to investigate the effects of etidronate on uCa/Cr in a prospective, randomised, placebo controlled clinical trial. All necessary criteria matched 81 women were divided into 3 groups at random, each group consisted of 27 patients. Prior to treatment, uCa/Cr was calculated from all subjects 3 hours after drinking 1 liter of water in the morning. Twenty seven (33.3%) women were randomised to oral doses of etidronate (400 mg/day for two weeks followed by drug free period of 10 weeks), twenty seven women to etidronate (400 mg/day for two weeks) plus calcium (1000 mg/day) for the following 10 weeks and twenty seven women to placebo (Fe, 50 mg/day) for 12 weeks. After 12 weeks of treatment, uCa/Cr declined significantly in the etidronate group from 0.118±0.064 to 0.053±0.021, in etidronate+calcium group from 0.08±0.03 to 0.06±0.015 ((p=0.004) and (p=0.005), respectively). In the placebo group no significant change was observed (p=0.03). In conclusion, etidronate is effective in postmenopausal women and the effectiveness of treatment may be followed up by measuring uCa/Cr which is a simple and cheap parameter of determining the effectivensess of etidronate in prevention of osteoporosis. However, since there are contradictory findings concerning uCa/Cr exist, larger clinical and prospective studies should be carried out.

🔖

Cite This Article

KÜÇÜK, Ş., ATMACA, R., GÖKDENİZ, R., TAŞKIN, Ö., URYAN, İ., BUHUR, A. (2022). Effect of etidronate on urinary calcium / creatinin ratio in postmenopausal women: A prospective, randomized, placebo controlled study. Turkish Journal of Medical Sciences, Cilt: 29 - Sayı: 6, 683–687. https://ajindex.com/articles/612493

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (18)

  1. Lindsay R. the menopause and osteoporosis. Obstet Gynecol. (suppl II). 1996; 87: 16S–19S
  2. McGowan JA. Osteoporois: assesment of bone loss and remodeling. Aging Clin Exp Res. 1996; 5: 81–93
  3. Compston JE, Cooper C and Kanis JA. Bone dansitometry in clinical practise. BMJ. 1995; 310: 1507–1510
  4. Reeve J. Future prospects for hormone replacement therapy. Br Med Bull. 1992; 48: 458–468
  5. Christiansen C. The different routes of administration and the effect of hormone replacement therapy on osteoporosis. Fertil Steril. 1994; 62: 152S–156S
  6. Davidson NE. Hormone replacement therapy–breast versus heart versus bone. N Engl J Med. 1995; 332: 1638–39
  7. Body JJ, Pot M, Borkowski A, Sculier JP and Klasterky J. A dose response study of aminohydroyprolidine biphosphonate in tumor–associated hypercalcemia. Am J Med. 1987; 82: 957–63
  8. Averbuch SD. New biphosphonate in the treatment of bone metastases. Cancer. 1993; 72: 3443–52
  9. Singer FR, Minoofar PN. Biphosphonates in the treatment of bone metabolism. Adv Endocrinol Metab. 1995: 6: 259–88
  10. Ott SM. Clinical effects of biphosphonates in involutional osteoporosis. J Bone Miner Res. 1993; 3 (suppl): 597–606
  11. Reginster YJ, Deroisy R, Danis D. Prevention of postmenopausal bone loss by tiludronate. Lancet. 1989; ii: 169–1471
  12. Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC III, Yanover MJ, Mysiw J, Kohse L, Bhaskar Rao M, Steiger P, Richmond B, Chesnut CH III. Intermittent cyclical eidronate treatment of postmenopausal osteoporosis. N Engl J Med. 1993; 323: 73–76
  13. Storm T, Thamsborg G, Steiniche T, Genant HG, Sorensen OH: Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N. Engl. J. Med. 322: 1265–71, 1990
  14. Rodan GA, Flesch HA. Biphosphonates: mechanism of action. J Clin Invest. 1996; 12: 2692–6
  15. Body JJ. Metastatic bone disease: clinical and therapeutic aspects. Bone 1992; 13: S57–S62
  16. Nordin BEC, Gallagher JC, Aaron JE et al: Postmenopausal osteopenia and osteoporosis. Estrogens in the postmenopause. Front Horm Res 3: 131, 1975
  17. Meunier PJ, Confavreux E, Tupinon I, Hardoim C, Delmas PD and Balena R. Prevention of early postmenopausal bone loss with cyclical etidronate therapy (A double–blind, placebo–controlled study and 1–year follow–up). J Clin Endocrinol. Metab. 1997; 82: 2784–91
  18. Heilberg IP, Martini LA, Teixeira SH, Szejnfeld VL, Cavalho AB,